PITTSBURGH — Mylan N.V. has launched doxycycline hyclate delayed-release tablets (200 mg), an antibiotic, in the United States.
Mylan said its doxycycline product is a generic version of Doryx 200-mg delayed-release tablets from Mayne Pharma.
A tetracycline-class antimicrobial, doxycycline hyclate DR tablets are a indicated as adjunctive therapy for severe acne.
U.S. sales of 200-mg doxycycline DR tablets totaled approximately $181.8 million for the 12 months ended March 31, according to IMS Health data reported by Mylan.
Mylan said that it was awarded 180 days of marketing exclusivity for its generic product after receiving final approval from the Food and Drug Administration for its supplemental Abbreviated New Drug Application (sANDA).
